BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) 41 th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.